A recombinant polypeptide corresponding to the C-terminal 129 amino acids of vitronectin exhibits heparin-binding affinity that is comparable to that of full-length vitronectin and is equally effective at neutralizing heparin anticoagulant activity. Results from this broad experimental approach argue that the behavior of the primary site is sufficient to account for the heparin binding activity of vitronectin and support an exposed orientation for the site in the structure of the native protein.
A recombinant polypeptide corresponding to the C-terminal 129 amino acids of vitronectin exhibits heparin-binding affinity that is comparable to that of full-length vitronectin and is equally effective at neutralizing heparin anticoagulant activity. Results from this broad experimental approach argue that the behavior of the primary site is sufficient to account for the heparin binding activity of vitronectin and support an exposed orientation for the site in the structure of the native protein.
Since the discovery of vitronectin in 1967, numerous studies have been conducted in an effort to characterize the structure and functions of this plasma and extracellular matrix protein (1) (2) (3) . The model of vitronectin that has emerged describes a multifunctional protein that interacts with a wide variety of macromolecules to regulate physiological processes, including complement-mediated cell lysis, cell adhesion, coagulation, and fibrinolysis. Sequence analysis and binding studies suggest a domain organization for vitronectin, with its functions mediated through individual elements aligned linearly along the sequence of the molecule (4 -9) .
The work to date supports the assignment of at least three domains within vitronectin. (i) The N-terminal domain consists of 44 amino acids that are identical to the circulating protein, Somatomedin B. Among these 44 amino acids are 8 cysteines that form 4 disulfide bonds. Binding sites for the anti-fibrinolytic protease inhibitor, PAI-1, 1 and for cell-surface receptors have been localized to this region of vitronectin. The Somatomedin B domain has been expressed in Escherichia coli as a functional protein that mimics the ability of vitronectin to bind and stabilize the active conformation of PAI-1 (10, 11) . (ii) The amino acids 131-268 and 269 -459 of vitronectin share homology with domains found in hemopexin and collagenase (12) . (iii) At the C terminus of vitronectin, a highly charged sequence interrupts the second hemopexin homology domain. This cationic sequence has been proposed to be the primary binding site for numerous ligands such as plasminogen, the complement C7, C8, and C9 components, PAI-1, and the widely administered anticoagulant drug, heparin (4, 5, 13) . A working model depicting the domain arrangement of vitronectin is presented in Fig. 1 .
The interaction between vitronectin and heparin is one of the most highly researched topics in the vitronectin literature. In 1983, vitronectin was shown to bind heparin-Sepharose (14) . Subsequent studies revealed that vitronectin neutralized heparin anticoagulant activity, suggesting a regulatory role for the glycoprotein in coagulation (15) . A search for the glycosaminoglycan-binding site within vitronectin localized binding activity to a C-terminal vitronectin fragment produced by digestion with cyanogen bromide (4) . Another group reported that a fragment corresponding to the C-terminal region of vitronectin bound heparin in ligand blotting assays and that synthetic peptides corresponding to the vitronectin residues 347-359 bound biotinylated heparin and diminished heparin activity (5, 16, 17) . Also, proteases such as thrombin and plasmin, which cleave vitronectin within the proposed heparin-binding se-quence, disrupt heparin binding to the protein (8, 18) . The amino acid sequence of the region shown to bind heparin is highly basic and contains two short sequences that correspond to consensus heparin-binding motifs that are found in many structurally unrelated heparin-binding proteins, including antithrombin III, thrombin, low density lipoprotein, and endothelial growth factor (19, 20) .
Although the sequence spanning residues 345-379 has been localized as a primary heparin recognition site, some workers have suggested that the charged sequence near the C terminus may not be solely responsible for heparin affinity. A report utilizing phage display indicates that sequences N-terminal to the cationic cluster may contribute to binding heparin (21) . Specifically, phagemid particles displaying the peptides Asp 82 -Cys 137 and Lys
175
-Asp 219 bound to heparin-agarose and to heparin immobilized on a microtiter plate. Also, recent work (22) in which nominal "domains" in vitronectin were expressed as fusion proteins with glutathione S-transferase indicated that the first hemopexin repeat in vitronectin exhibited some heparin binding activity. However, neither of these studies characterized affinities of the recombinant polypeptides for heparin.
There has been controversy about the degree of exposure of the heparin-binding sequence in native vitronectin. It was originally assumed that the heparin-binding sequence was encrypted in the native fold of the molecule (19) , but more recent work from this laboratory has demonstrated that the heparinbinding site is fully exposed in native vitronectin (23) . Confusion over the degree of exposure of sites within the conformationally labile protein had stemmed primarily from the application of varied preparation protocols that produce vitronectin forms that differ in oligomeric state. Also, the solidphase assays in widespread use for measuring heparin binding are inadequate to distinguish changes in affinity from changes in numbers of binding sites (23, 24) . Solution binding measurements of heparin with different forms of vitronectin underscore the importance of a rigorous determination of both binding strengths and numbers of binding sites for a proper understanding of the heparin-vitronectin interaction (23, 24) . Only with both pieces of information was it possible to show the exposed orientation of the heparin site, with comparable affinities for both the native and altered forms of vitronectin.
Is it correct to assume that all of the sequence information necessary for heparin binding is present within the cationic sequence near the C terminus of vitronectin? Does liberation of the heparin-binding sequence from N-terminal sequences in vitronectin support the argument that the heparin-binding sequence is exposed in native vitronectin? Just as it has been critical to use quantitative measurements to demonstrate the exposed orientation of the primary heparin-binding site on vitronectin, it is important to use rigorous methods to address these questions critically. A variety of approaches, including solution binding analyses, NMR, and recombinant methods, were used to address these issues. According to these studies, the relative importance of secondary glycosaminoglycan-binding sites on vitronectin appears to be minimal.
EXPERIMENTAL PROCEDURES
Materials-Vitronectin was purified from human plasma by a modification of the original protocol of Dahlback and Podack (25) , as described (26) . Human thrombin and antithrombin were generously provided by Dr. Frank C. Church (Department of Hematology, University of North Carolina, Chapel Hill, NC). Synthetic peptides derived from the sequence of the heparin-binding region of vitronectin were obtained from Chiron Mimetopes. The peptides were more than 85% pure and were used without further purification. Heparin fractions from porcine mucosa with average molecular weights of 3000, 6000 and 15,000 (Grade 1-A) and the glycosaminoglycans, dextran sulfate, heparan sulfate, and fucoidan, were obtained from Sigma. Polyclonal antibodies
FIG. 1. Domain arrangement of vitronectin.
A working model for the domain arrangement of vitronectin is depicted. The Somatomedin B domain is shown in blue. The tertiary structure of this domain is stabilized by four disulfide bonds, shown in yellow. The sequence flanking the Somatomedin B domain (shown in green) contains the RGD cell-binding motif. The hemopexin homology domains are shown in red. The structure of these regions was loosely based on the known ␤-structure of the hemopexin C-terminal domain (57, 58) . Interrupting the second hemopexin domain, the heparin-binding sequence is shown in pink and exposed on the surface of the molecule. A disulfide bond is known to exist between the two hemopexin domains. This is depicted in yellow. Two free sulfhydryls (shown in yellow) are buried within the interior of vitronectin (29) ; one of these has been identified in this laboratory as Cys-411. (Two cysteines are present in human plasma-derived vitronectin at positions 411 and 453. It is well established that one of these must participate in disulfide bond formation with a cysteine N-terminal to the endogenous protease cleavage site at position 379, since the C-terminal proteolytic fragment is only released under denaturing conditions.) against human vitronectin were produced at Rockland Laboratories. Goat anti-rabbit IgG linked covalently with horseradish peroxidase was obtained from Vector Laboratories. Chromozym-TH was purchased from Boehringer Mannheim. Urea was obtained from ICN. All other chemicals were of the highest grade commercially available and were used without additional purification. Heparin labeled with the fluorescent coumarin probe was prepared as described previously (23) .
Expression and Purification of the Recombinant C-terminal Domain (rCTD)-The cDNA for human vitronectin (27) was obtained from Dr. Erkki Ruoslahti (The Burnham Institute, La Jolla, CA) and cloned into pT7-7 (28) . Using an intrinsic NcoI site in the vitronectin sequence and a 3Ј HindIII site from pT7-7, the DNA coding for residues Met 330 to Leu 459 was cloned into the pET23d (Novagen) expression vector. In this recombinant vector, transcription was under control of the T7 promoter, with an internal methionine (Met 330 ) from the vitronectin sequence serving as a start codon for translation of the recombinant protein, rCTD. The recombinant plasmid was transformed into competent BL21(DE3)pLysS cells (Novagen). Transformants were grown to midlog phase in LB containing 50 g⅐ml Ϫ1 ampicillin and 34 g⅐ml chloramphenicol, followed by induction with the addition of isopropylthiogalactoside to 1.0 mM. Cells were harvested 8 -16 h post-induction by centrifugation; total cell lysates were analyzed by gel electrophoresis on a 15% SDS-polyacrylamide gel stained with Coomassie Brilliant Blue. The recombinant vitronectin polypeptide fragment was detected by Western blot analysis using a polyclonal antiserum for vitronectin. For purification, the rCTD was expressed in 250 ml of LB cultures after induction with isopropylthiogalactoside. Cells were harvested after overnight growth at 37°C by centrifugation, and cell extraction was performed by freeze-thaw, with the addition of a sonication step (three 10-s bursts at the highest intensity) after each freeze-thaw cycle. After centrifugation, the pellet was resuspended in 1/10 the original culture volume with 8 M urea in HCB (20 mM Tris, 20 mM NaCl, 0.1 mM EDTA, pH 7.4) and applied to a heparin-Sepharose column. The column was washed sequentially with the denaturing HCB containing 20 mM NaCl and 0.15 M NaCl. Purified rCTD was eluted in denaturing HCB buffer containing 1.0 M NaCl. Fractions were analyzed for purity by SDSpolyacrylamide gel electrophoresis. The purified recombinant fragment of vitronectin was stored at pH 4.0, conditions under which it exhibited optimal solubility, following dialysis into either Glycine buffer (0.1 M glycine, 0.15 M NaCl, pH 4.0) or Acetate buffer (0.1 M sodium acetate, 0.15 M NaCl, pH 4.0). In the presence of heparin, the rCTD was also highly soluble at neutral pH.
Equilibrium analytical ultracentrifugation was used to evaluate the size of the purified recombinant protein. Experiments were performed using a Beckman Optima XL-A or Optima XL-I instrument, essentially as described (29) . The best fit of the data observed for rCTD in Acetate buffer indicates that the protein is a mixture of oligomeric forms, predominantly an approximate 60,000 molecular weight species, with a minor component that is more highly aggregated. The molecular weight for the rCTD monomer was calculated from the amino acid sequence to be 15,100.
Fluorescence Spectroscopy for Binding Measurements-Vitronectin binding to heparin was measured by fluorescence spectroscopy, using a molecular weight-fractionated heparin sample that had been labeled with a coumarin probe according to the method described by Zhuang et al. (23) . For experiments designed to measure salt-induced dissociation of heparin from vitronectin, the binary complex was formed initially by mixing vitronectin and coumarin-labeled heparin in equal concentrations of 2 M in 2 ml of 20 mM sodium phosphate, pH 7.4. The fluorescence of the coumarin probe in the complex was measured at 480 nm using an excitation wavelength of 430 nm. Small volume aliquots of a 5 M NaCl solution in the same buffer were added, and the fluorescence emission intensity was again recorded. Aliquots of NaCl were added until the fluorescence emission intensity had reached a plateau at values that were nearly equivalent to those measured for coumarinheparin in the absence of added vitronectin.
Competition of dextran sulfate, heparan sulfate, or fucoidan for heparin binding to vitronectin was measured by displacement of bound coumarin-labeled heparin from vitronectin. The fluorescence of a mixture of 5 M labeled heparin (M r ϳ6000) and 5 M vitronectin (150 l total volume) was measured as the starting point (F max ) in the competition experiments. Fluorescence was then recorded as aliquots of concentrated solutions of glycosaminoglycans (625 M dextran sulfate, 200 M fucoidan, or 690 M heparan sulfate) were added to the cuvette so that the added volume was no greater than 15%. Fluorescence emission measurements (F) were taken at 480 nm with the excitation monochromator set at 430 nm. The F obtained was averaged for three measurements and corrected mathematically for dilution. Data were analyzed as described (23, 30) using Equation 1 to give estimates of binding affinity and stoichiometry for the competing ligands. (23) . Changes in intrinsic tyrosine fluorescence were used for measurements of peptide binding to heparin. Fluorescence spectra were recorded using a Perkin-Elmer model LS-5B at room temperature with a 2-ml sample and 1-cm path length cells. Peptide was diluted to a final concentration of 5 M in 50 mM HEPES buffer, pH 5.0. Small volume aliquots of heparin were added, and the fluorescence emission (F) at 305 nm (10-nm slit width) was recorded using an excitation wavelength of 275 nm and a 5-nm slit width. Fluorescence data were mathematically corrected for dilution upon addition of titrant. The data were expressed as ⌬F/F 0 in which ⌬F ϭ F Ϫ F 0 , and F 0 was the starting fluorescence of the sample. The values for ⌬F were plotted as a function of vitronectin concentration and were fit to Equation 2 using nonlinear least squares analysis as follows:
where R is the peptide concentration; T is the total heparin concentration; and K d is the dissociation constant. The same equation was also used to give an estimate for the stoichiometry of binding of the rCTD to heparin for the titrations using intrinsic fluorescence of the rCTD, as described below. Heparin binding to the rCTD was measured by monitoring changes in the intrinsic tryptophan fluorescence of the proteins upon addition of small volume aliquots of heparin. Fluorescence measurements were made using a quartz cuvette (Hellma) with a 1-cm path length using a Perkin-Elmer LS50B luminescence spectrometer. To minimize protein adsorption, the cuvettes were coated with lipids (31, 32) , and the titrations were performed at low pH, where the recombinant protein was optimally soluble. Protein samples (350 nM) in a total of 1.0 ml of 0.1 M Acetate buffer, pH 4.0, containing 0.15 M NaCl and 0.1% polyethylene glycol-8000 were titrated with small volumes of highly concentrated solutions of heparin. The tryptophan fluorescence was measured after each addition using an excitation wavelength of 290 nm, with the emission wavelength set at 340 nm. The intensity of fluorescence (F) recorded was the average of three readings. Control titrations of heparin into buffer in a reference cuvette were used to obtain F 0 values. The data were plotted as a function of titrant concentration and fit to the Hill equation (Equation 3) using nonlinear least squares analysis.
where S is the total titrant concentration; K 0.5 corresponds to the titrant concentration at half-maximal saturation; and n is the Hill coefficient.
Cyanogen Bromide Mapping of HOCGO-labeled VitronectinVitronectin was labeled with HOCGO as described previously (33) . The labeled protein was digested with cyanogen bromide as described by Suzuki et al. (4) . Peptides were purified by reversed-phase high pressure liquid chromatography on a Phenomenex Jupiter C18 column (4.6 ϫ 250 mm) using a Beckman System Gold instrument for gradient programming and data collection. Peptides generated by cyanogen bromide treatment were separated at a 1 ml/min flow rate in a three-step gradient, running from 0 to 40% solvent B over 10 min, 40 -70% B over the next 30 min, and then 70 -100% B in the final 20 min. Solvent A contained 0.1% trifluoroacetic acid in water, and solvent B contained 0.1% trifluoroacetic acid in acetonitrile. The fractions were monitored at 220, 280, and 370 nm (for the HOCGO chromophore), and the peaks were collected manually. Automated peptide sequencing was performed at the sequencing facility of the University of Tennessee Medical Center, Knoxville, TN, by the Edman degradation method using an instrument from Applied Biosystems, Inc.
Sample Preparation for NMR Studies-Synthetic peptides were dissolved in 90% H 2 O, 10%
2 H 2 O in a total volume of 500 l yielding a final concentration of 9 mM. The pH of the sample was adjusted to 5.0 Ϯ 0.1 to reduce exchange rates for exchangeable protons. Peptides were deu-terated by repeated lyophilization and dissolution in 2 H 2 O for studies involving nonexchangeable protons only. The pH values of the solutions in 2 H 2 O are reported without correction of the pH-meter readings. A heparin-peptide complex was prepared by adding heparin in a single addition to give a final heparin concentration in slight excess over that of the peptide. NMR Spectroscopy-All 1 H NMR spectra were recorded on a wide bore Bruker AMX 400 spectrometer operating at 400 MHz for protons. Standard two-dimensional 1 H-1 H COSY, DQF COSY, NOESY, and HOHAHA (34 -36) data sets were collected in the phase-sensitive mode using the time proportional phase increment method (37) . 2K data points were recorded in t 2 for each of 221-364 t 1 values, with 128 transients per t 1 increment. The spectral width was 4032 Hz. The HOHAHA pulse program contained an MLEV 17 spin lock sequence (34) which was preceded and followed by two 2.5-ms trim pulses. NOESY spectra were recorded with mixing times of 200, 250, 300, and 400 ms. All mixing times were varied randomly by 5%. HOHAHA experiments were recorded with 4 mixing times ranging from 24.2 to 101 ms (including trim pulses). The data were zero-filled to 1K points in t 1 and were multiplied by a shifted sin (for COSY) or (sin) 2 (for NOESY, ROESY, HOHAHA) window function before Fourier transformation. Phase corrections and base-line corrections were performed in both dimensions.
Kinetic Analysis-The rate of inactivation of thrombin by the protease inhibitor, antithrombin, in the presence of heparin was measured continuously using the chromogenic thrombin substrate, Chromozym-TH (38) . Reactions were performed in a 1-ml reaction volume in acrylic cuvettes (Sarstedt) at 23°C in a buffer of 40 mM sodium phosphate, pH 7.4, containing 0.15 M NaCl and 0.1% polyethylene glycol-8000. Heparin with an average molecular weight of 6,000 was used in the reactions at a concentration of 66.0 nM. The initial concentrations of Chromozym-TH, thrombin, and antithrombin were held constant at 0.19 mM, 2.0 nM, and 60.0 nM, respectively. Varying concentrations of rCTD in 8.0 M urea were mixed with heparin prior to dilution into the reaction mixture in order to ensure solubility. The urea concentration was maintained at 0.8 M for all reactions by adding necessary volumes of 8.0 M urea. Pseudo-first order rates of reaction (K app ) were determined by non-linear least squares analysis using the IGOR software package (Wavemetrics, Oswego, OR). These data were plotted against the concentration of vitronectin or rCTD, and the K i was determined from the concentration of vitronectin that reduced the K app by 50%. The K i values for plasma-derived vitronectin were the same in 0 and 0.8 M urea, indicating that the low urea concentration used in the assay did not affect the interaction between heparin and vitronectin. Additionally, unfolding studies indicate that vitronectin structure is not affected at this low urea concentration (26, 29) .
RESULTS
In an attempt to more thoroughly evaluate the types of interactions that characterize binding of human plasma vitronectin to heparin, a multi-faceted approach was used that combined solution biochemistry, spectrometry, and recombinant approaches. Experiments were designed to evaluate ionic versus non-ionic interactions in this context, to identify potential residues that contribute to the interaction, and to assess further the extent to which the primary heparin-binding sequence is exposed on the surface of vitronectin.
Evaluation of the Ionic Strength Dependence of Heparin Binding to Native Vitronectin Indicates a Single Ionic Interaction to
Be Important-Recently, a quantitative method that uses changes in the fluorescence of an extrinsic probe on heparin to measure the affinity and stoichiometry of heparin binding to vitronectin has been reported from this laboratory (23) . The assay has proven to be extremely informative and has indicated that the heparin-binding site in native vitronectin is exposed and functional, arguing against the "cryptic" orientation that had originally been proposed on the basis of more qualitative measurements. In this study, the fluorescence assay was employed to systematically evaluate the ionic strength dependence of the binding interaction and evaluate the number of charged interactions that contribute to the binary interaction between heparin and vitronectin. As shown in Fig. 2A , the binding of heparin to vitronectin is a sensitive function of ionic strength, and modest salt concentrations completely displace heparin from the protein. Fig. 2B shows a treatment of the equilibrium binding data measured at different ionic strengths according to classical linkage theory (39, 40) . The slope of the curve presented in Fig. 2B is equal to ϳ1, indicating the contribution of one ionic interaction to the overall binding free energy at physiological pH. This result contrasts with similar measurements for heparin binding to antithrombin III, in which 5-6 ionic interactions are involved in binding (41) . This difference has practical consequences, as antithrombin III has an affinity for heparin that is at least 2 orders of magnitude higher, and it binds to a heparin affinity column at much higher ionic strengths than observed for vitronectin (42) .
Sulfated Glycosaminoglycans That Bind to Vitronectin Compete with Heparin for the Binding Site-Other investigators have shown that vitronectin exhibits affinity for certain highly sulfated glycosaminoglycans, including dextran sulfate and fucoidan, in addition to heparin (43, 44). These ligands were tested as competitors with heparin in the fluorescence assay for binding to vitronectin. As shown in Fig. 3 , both of these glycosaminoglycans are fully competitive with heparin for binding to vitronectin. At fairly low concentrations, both ligands displace heparin from vitronectin so that the fluorescence of the labeled heparin is indistinguishable from the fluorescence measured in A, an initial complex between vitronectin and coumarinheparin was formed by mixing equimolar concentrations of protein and labeled heparin in phosphate buffer without NaCl, as described under "Experimental Procedures." Dissociation of the heparin-vitronectin complex by addition of NaCl was measured by the decrease in fluorescence intensity of the coumarin probe attached to heparin. Fluorescence intensity data (F) are expressed relative to the initial fluorescence of the probe in the complex (F 0 ) as a function of added NaCl, plotted on a logarithmic scale. B, data from equilibrium binding measurements using coumarin-labeled heparin (23) are plotted as a function of ionic strength. The slope of this plot, equal to 0.99, is indicative of the number of ionic interactions involved in binding.
the absence of added protein (Fig. 3A) . Analysis of these data for binding affinities and stoichiometries as described previously (23, 30) indicated tighter binding to vitronectin of both of the highly sulfated glycosaminoglycans, with K d values of 0.4 and 0.06 M for dextran sulfate and fucoidan, respectively, compared with ϳ5 M for heparin (Fig. 3B) . The stoichiometry of binding of dextran sulfate (M r ϳ8000) to vitronectin is 1:1, whereas the stoichiometry of fucoidan (M r ϳ50,000):vitronectin binding is 1:4. Thus, the larger polysaccharide exhibits more binding sites for the protein, a property that is a straightforward function of the size of the glycosaminoglycan (45) . More important is the conclusion from these analyses that binding of these ligands involves only a single class of binding sites, as the model described in Equation 1 with only a single binding site affinity gives adequate fits to the data in Fig. 3A . This result is compatible with the fact that all previous analyses from this laboratory for binding of heparin to vitronectin have been adequately modeled with only a single class of sites on the protein (24) .
Also shown in Fig. 3A are competition data for heparan sulfate binding and displacing heparin from vitronectin. Heparan sulfate has previously been shown to have weaker effects on vitronectin immunoreactivity or structure compared with the more highly sulfated glycosaminoglycans (43, 44). These data indicate a weaker affinity for vitronectin since heparan sulfate does not completely displace heparin from the protein at the concentrations used in these experiments.
Critical Arginine(s) That Affect Heparin Binding Are Localized within a Cyanogen Bromide Fragment That Contains the C-terminal Cationic Cluster-The primary heparin-binding sequence within vitronectin has been localized by proteolysis and studies with synthetic peptides (5, 17) to the sequence from 341 to 380. This region identified includes the 18-residue sequence, (346)LAKKQRFRHRNRKGYRSQ(363), exhibiting a pattern of cationic amino acids that aligns with consensus heparin-binding sequences derived from comparison of a large number of heparin-binding proteins (19, 20) . In a previous study to test for specific arginine residues involved in the interaction, vitronectin was reacted with an arginine-specific coumarin reagent (33) . Labeling of 1-2 arginines in vitronectin impairs heparin binding (33) . Peptide mapping has now been used to identify the region of the protein that is labeled. Cyanogen bromide, which was originally used to identify the fragment-(340 -381) as the heparin-binding region (5, 17) , was added to digest labeled vitronectin, and the digestion fragments were separated by reverse-phase high pressure liquid chromatography (data not shown). Sequencing of the eluted fragments shows at least 80% of the total label from the reaction is found within the heparin-binding region on the 340 -381 fragment. When vitronectin was labeled with the coumarin probe in the presence of heparin, there was much less incorporation of label, and the quenching behavior of the probes was different compared with the exposed label on the heparin-binding region (33) . These studies support other work from this laboratory in the following ways: by demonstrating the accessibility (and thus surface orientation) of the reactive arginines, by providing separate evidence for the contribution of only a small number of arginine residues to the ionic interaction with heparin, and by localizing these residues to the C-terminal cationic cluster. Because of the challenge of identifying which of the numerous arginines within the 340 -381 fragment contain the coumarin label by standard peptide mapping approaches, an NMR analysis was pursued to evaluate a potential role of individual amino acids in heparin binding.
Peptides Derived from the Primary Heparin-binding Site Were Characterized by NMR-Synthetic peptides derived from the primary heparin-binding region within vitronectin have been used extensively to delineate structure-function relationships in the protein, and two such peptides were characterized using NMR approaches in this study. Fig. 4 lists the sequences of several peptides that have been used in mapping functional sites on vitronectin, including the 40-amino acid peptide originally isolated as a heparin-binding cyanogen bromide fragment (4) and the consensus heparin-binding motifs derived from sequence analyses of members within a family of heparinbinding proteins. The two peptides used in this study are listed at the bottom of the figure for comparison with the various sequences. The first of these peptides, PEPTIDE 1, is an 18-residue sequence that encompasses peptides that have been widely used in vitronectin structure-function work (5, 17, 46, 47) . It contains both of the consensus sequences derived by Cardin and Weintraub (20) , as well as the single consensus motif reported in the work of Sobel et al. (19) . Note that the 18-mer is both highly charged and highly redundant in se- (23) . These values were used to generate the non-linear fits to Equation 1 for the data shown in A for dextran sulfate, heparin, and fucoidan. The curve through the heparan sulfate data in A is for illustrative purposes only.
quence, containing 5 arginine residues, 1 histidine residue, and 3 lysine residues.
One-dimensional proton NMR and two-dimensional spectra (NOESY and COSY, data not shown) were collected on the 18-residue peptide sample. Not surprisingly, the analyses were not adequate to provide sequence-specific assignments for the multiple charged residues in the peptide. Another impediment to evaluating heparin-binding properties of the peptide was the formation of an insoluble aggregate upon addition of ligand. Attempts to minimize precipitation of the heparin-peptide complexes by modifying pH and ionic strength conditions were unsuccessful. The formation of an insoluble aggregate in this work with PEPTIDE 1 calls into question earlier work with some of the other peptides (e.g. peptide a in Fig. 4 (17, 46) ) in which tight binding affinity for heparin was reported. Since there is not a ready equilibrium between solid and solution phases, true binding affinities cannot be calculated under these conditions and will be artifactual in nature.
Because of these technical obstacles and the inability to get sequence-specific information from the highly redundant sequence, the NMR characterization was focused on the 14-residue peptide listed in Fig. 4 as PEPTIDE 2. This peptide includes only one of the two consensus heparin-binding motifs and contains less dense positive charge, with two lysines, two arginines, and one histidine. The 14-mer also incorporates strategic replacements. (i) At positions 1 and 13 in PEPTIDE 2, arginines are replaced by glycine and alanine, respectively. Note that the arginine residue replaced at either position does not correspond to a basic residue in any of the consensus sequences listed. These substitutions were made in the sequence with the intention of simplifying the sequence-specific assignments in the NMR work by reducing the redundancy of amino acids in the peptide. It was reasoned that alanine and glycine can be accommodated in any given secondary structure that would be optimal for the sequence. (ii) Furthermore, the replacement of tyrosine for phenylalanine at position 13 is a conservative replacement that was introduced to provide an intrinsic fluorescent probe within the sequence of the peptide.
Heparin binding to PEPTIDE 2 did not give the problematic aggregation observed with PEPTIDE 1, and a K d for the interaction with PEPTIDE 2 was estimated by fluorescence spectroscopy. Using the internal tyrosine in the 14-residue peptide from vitronectin as a fluorescent probe to monitor heparin binding gave an enhancement in fluorescence of the tyrosine that clearly titrates as the peptide becomes saturated with ligand (Fig. 5) . Fitting of the binding isotherm, as shown by the smooth curve in the figure, resulted in a dissociation constant of 150 M for the interaction of heparin with the peptide. Low molecular weight heparin was used in this experiment to minimize the potential for binding of multiple peptide sequences to a single heparin chain, and the fitting of the data indicates a 1:1 stoichiometry of binding.
One-dimensional NMR, combined with COSY, HOHAHA, NOESY, and ROESY experiments, provided sequence-specific assignments for the majority of the protons in PEPTIDE 2 (data not shown). There was little chemical shift dispersion observed in the C-␣H and upfield regions of the NMR spectra of the peptide, suggesting a random conformation of the peptide in solution. This result is not particularly surprising given the high density of positive charge that would lead to repulsion and oppose adoption of an ordered, collapsed structure. The specific assignments of the charged residues were much more successful with this peptide compared with PEPTIDE 1. However, site-specific assignments were not achieved for the two lysine residues, as chemical shifts for all protons on these residues were indistinguishable in NMR spectra. Similarly, the C-␤ proton of leucine and the side chain NHs of the two arginines were not differentiated due to resonance overlap.
NMR Analysis of the Complex between Heparin and the Peptide Indicates Charged and Uncharged Residues to Be Involved in the Binding
Interaction-One-dimensional spectra (data not shown) indicated that there is very little spectral overlap between the peptide and heparin, thus providing a favorable situation for studies on the heparin-peptide interactions by NMR. Upon addition of saturating heparin concentrations, the one-dimensional spectrum exhibited changes in the region of the arginine C-␦H and lysine C-⑀H proton chemical shifts (3.0 -3.3 ppm), which indicate that one or more basic residues are affected by the formation of the heparin-peptide complex. The intensity of the resonance at 3.3 ppm decreased, indicating that an arginine C-␦H group is shifted downfield under the heparin resonances or broadened in the binary heparin-peptide complex. In concert with these observations, the side chain NH resonances of arginine and lysine residues were also affected strongly, suggesting that the exchange rates of these protons were altered significantly. Furthermore, both the C-2 and C-4 figure, with B representing a basic amino acid (lysine, histidine, or arginine) and X representing a non-basic amino acid. Amino acids within the sequence of vitronectin that correspond to consensus residues are highlighted in bold. The 40-residue sequence in the center of the figure represents the cyanogen bromide fragment spanning residues 341-380 within the sequence of human vitronectin that was shown to bind to heparin by affinity chromatography (4). Peptide a was used as a competitor for heparin binding in kinetic studies measuring the heparin-promoted inhibition of factor Xa by antithrombin. Peptides b and c were observed to bind heparin in solid-phase assays. The two sequences (PEPTIDES 1 and 2) that are listed at the bottom of the figure are characterized in this study. Amino acid substitutions that were made within the sequence of PEPTIDE 2 are underlined (see text). Citations referenced in the figure are as follows: 1 The expanded amide/aliphatic region of the NOESY spectra recorded with the peptide-heparin complex at 300 K is shown in Fig. 6 . Two marked NOE cross-peaks in the NOESY spectrum of the binary complex most likely represent intermolecular NOEs from heparin to the following: (i) the C-␦H of arginine (marked A) and (ii) the ␣-NH of glutamine or arginine 9 (marked B). In contrast to this, in the spectra recorded with peptide alone, only a few cross-peaks corresponding to sequential H-␣ i /NH iϩ1 interactions and NH-CH side chain interactions were observed, and their intensities were barely above the noise level. Addition of heparin gives rise not only to new cross-peaks but also increases the intensity of some of the observed NOEs that correspond to NH/side chain and intermolecular interactions.
Heparin Binds with High Affinity to a Recombinant C-terminal Domain (rCTD)-To complement the equilibrium binding measurements, peptide mapping and detailed spectrometry, a recombinant fragment of vitronectin was cloned into an expression vector to allow facile production in a prokaryotic system. The C-terminal 129 amino acids were selected for expression to encompass the primary heparin-binding site identified in vitronectin within the context of the second hemopexin domain. The recombinant polypeptide expressed in this work differs somewhat from the "hemopexin 2" domain expressed and partially characterized recently (22) , as the rCTD is 60 amino acids shorter in sequence, beginning further downstream at methionine 331 so that it is missing vitronectin residues 270 -330. Another major difference between the constructs is that the rCTD used in this work is not a fusion protein, whereas the hemopexin 2 domain characterized by and Yoneda and coworkers (22) contained a large N-terminal glutathione S-transferase fusion. The oligomeric nature of the recombinant polypeptide used in this work was explicitly determined by analytical ultracentrifugation to be predominantly a tetramer. Other recombinant fragments from vitronectin, such as the fusion protein used by Yoneda et al. (22) , have an unknown oligomeric structure.
The region of vitronectin expressed in rCTD contains 3 tryptophans, providing convenient intrinsic fluorescent probes to (23) and other heparin-binding proteins (45) . The binding stoichiometry using low molecular weight heparin (Mr ϳ 3,000) is approximately 1 mol of rCTD per mol of heparin. When the heparin size is increased to 6000, the stoichiometry increases to about 2 mol of rCTD bound per mol of heparin, and approximately 6 rCTD bind to a heparin chain with a molecular weight of 15,000.
A sigmoidal shape is noted in the binding curves, suggestive of a cooperative interaction between the glycosaminoglycan and the recombinant protein, which is a tetramer. The data were therefore fit to a Hill equation. For large molecular weight heparin, the K 0.5 was calculated to be approximately 5 nM. This value was somewhat larger for low molecular weight heparin, indicative of weaker binding with smaller heparin chains. As would be expected, the increased number of binding sites on larger heparin molecules strengthens the binding affinity with oligomeric rCTD. Control experiments measuring heparin binding to full-length plasma vitronectin at pH 4.0 gave a comparable K d of 12 nM (data not shown). 2 This pH was used for the binding experiments with the rCTD to mimic conditions that give optimal solubility of the recombinant protein in the absence of heparin and ensure that there were no non-equilibrium or light scattering artifacts in the measurements. The tighter binding to heparin observed below the pI of the protein is a predictable function of the net positive charge on the protein or polypeptide.
The Recombinant Heparin-binding Domain from Vitronectin Neutralizes Heparin Anticoagulant Activity-Heparin binding to the recombinant proteins was also measured using a kinetic assay that has previously been employed to analyze vitronectin binding to heparin. This assay is based on the ability of vitronectin to compete with other proteins for binding to heparin (48) . Thrombin is inactivated upon binding the serine protease inhibitor, antithrombin. Although this reaction is nor- mally slow, heparin increases the rate of reaction between thrombin and antithrombin by several orders of magnitude. However, molecules like vitronectin, which compete with the protease and/or its inhibitor for heparin binding, can neutralize the heparin-catalyzed inactivation of thrombin. The ability of molecules to compete for heparin binding is measured by monitoring the rate of inactivation of thrombin by antithrombin in the presence of heparin and testing increasing concentrations of the competing molecule for effects on the rate. When the rCTD was evaluated in this assay, it neutralized the heparincatalyzed inactivation of thrombin. The rate of inactivation of thrombin decreased significantly and eventually reached a plateau upon the addition of high concentrations of recombinant protein (Fig. 8) . The K i for the interaction is 0.3 M with rCTD. Plasma-derived vitronectin competes for heparin binding in the same assay with a K i of approximately 0.4 M. These data indicate that rCTD neutralizes the anticoagulant activity of heparin as effectively as full-length plasma vitronectin. It is apparent from these data that the elements critical for binding and neutralizing heparin are present within the recombinant C-terminal polypeptide.
DISCUSSION
There has been considerable discussion in the vitronectin literature concerning the relationship between the structure and function of the protein. Vitronectin is believed to be a multifunctional protein with ligand-binding functions localized to independent domains in the molecule. However, the large size and conformational lability of vitronectin has precluded structural characterization of the protein by crystallography or NMR. In the absence of a three-dimensional structure, domain assignments have been based on the ability of monoclonal antibodies, synthetic peptides, or proteolytic fragments to compete with plasma-derived vitronectin for ligand binding.
The goal of this study was to elaborate on the domain model for vitronectin, presented in Fig. 1 . Aspects of the model that merit further consideration include the following: (i) the identification of critical structural elements within the consensus heparin-binding site for binding to glycosaminoglycans; (ii) the relative importance of recently identified secondary heparinbinding sites; (iii) the potential for structural alterations in multimeric vitronectin to influence the relative importance of primary and secondary heparin-binding sites in the protein; and (iv) the extent of exposure of the primary heparin-binding site on the surface of native vitronectin, a point of some controversy since the historical model for vitronectin structure and function had proposed a buried site (17) . Toward these aims, a more rigorous examination of glycosaminoglycan binding to vitronectin in solution has been pursued. Furthermore, arginine residues within vitronectin that are modified with a fluorescent probe, resulting in a diminution of heparin binding activity, have been localized by peptide mapping to the cyanogen bromide fragment containing the primary heparin-binding site. Also, synthetic peptides that are based on this primary heparin-binding site of vitronectin have been characterized by NMR in isolation and in complex with heparin to give insight into particular types of interactions that are important. Finally, a recombinant heparin-binding domain from vitronectin has been thoroughly characterized according to heparin-binding properties and shown to bind the ligand with nearly identical affinity as that of plasma vitronectin. These results together have bearing on each of the aspects of the domain model for vitronectin that have been raised for discussion.
What Are the Critical Structural Elements for Heparin Binding?-Previous work from this laboratory had demonstrated that the dissociation constant for the binding of heparin to vitronectin was dependent on ionic strength (23) . If data are analyzed to predict the number of ionic interactions that contribute to the binding of heparin to the protein, the result is that only a single ionic interaction appears to be prominent for binding of the ligand. This result is unexpected because the primary heparin-binding sequence in vitronectin is argininerich so that more than one charged contact would be possible Binding to the protein sample was analyzed using three different heparin stocks with average molecular weights of 15,000 (circles), 6,000 (squares), and 3,000 (triangles). The raw data were analyzed as described under "Experimental Procedures" to obtain the values for ⌬F. The data were normalized by dividing ⌬F by ⌬F max for each titration to obtain the fractional saturation values and were fit using the Hill equation (Equation 3) to obtain the binding isotherm shown (solid line).
FIG. 8. Heparin neutralization by the rCTD and vitronectin.
Heparin activity was measured by an increase in the reaction rate of antithrombin inactivation of thrombin. The concentration of active thrombin was monitored continuously over time by hydrolysis of the Chromozym-TH substrate as described under "Experimental Procedures." The effects of the rCTD (squares) or plasma vitronectin (circles) on the reaction kinetics were measured at varying concentrations and are standardized to the reaction rate of heparin-catalyzed inhibition in the absence of the vitronectin-derived polypeptide. The smooth curves shown are for illustrative purposes only and do not represent mathematical fitting of the data.
between the protein and ligand. However, this result is in accordance with the observation that native vitronectin exhibits a fairly weak affinity for heparin (in the 5-10 M range (23)) at low ionic strengths, and the affinity is diminished at physiological ionic strengths. It is also consistent with the observation from previous work that the modification of only 1-2 arginines impairs heparin binding to vitronectin (33) . This study has taken the previous observation a step further by demonstrating that the fluorescent probe introduced in the chemical modification experiments is localized to a cyanogen bromide peptide fragment-(341-380) containing the primary heparin-binding sequence.
A synthetic peptide derived from this primary heparin-binding sequence in vitronectin was studied by NMR as a model to evaluate ionic and other interactions that contribute to proteinligand affinity. Indeed, although there are numerous possible ionic contacts that might have been observed for the binary complex, only a single charge-charge interaction is observed from the NOESY analysis. An arginine residue is responsible for this contact, although it is not possible from the spectra to distinguish between the two arginines in the peptide (which correspond to Arg 351 and Arg 353 in vitronectin). Valuable insight into the nature of the interaction was also gained from the demonstration of other types of contacts with the peptide involving nonionic interactions with glutamine or asparagine. Note that these interactions are made via side chains rather than the peptide backbone, indicating some degree of specificity conferred via these interactions that is not predicted by the consensus motif that merely specifies basic versus nonbasic amino acids within the sequence. Thus, binding strength also appears to be a function of the context within which the consensus sequence is found. Glutamine, asparagine, and tyrosine residues have been observed to contact ligands in the saccharide-binding sites of several other proteins (49) .
The model peptide used in this study exhibited relatively weak binding to heparin. It is common that isolated peptides exhibit lower affinity for their ligands than intact proteins, and this result presumably indicates that the bulk of the sequence is important for maintaining the binding site in its proper conformation. This 14-residue peptide was not sufficiently long to adopt an ordered structure, although this region in the intact protein is thought to assume a ␤-sheet conformation. Naturally, in addition to a conformational role, residues outside this 14-amino acid sequence could directly contribute to binding.
Because of the relatively weak binding exhibited by the peptide and the inability to distinguish between multiple arginine residues by NMR, an alternative system for studying heparin binding was a recombinant polypeptide containing the C-terminal 129 amino acids from vitronectin. The rCTD was capable of neutralizing heparin activity in a kinetic assay measuring its ability to inhibit the heparin-catalyzed inactivation of thrombin by antithrombin. It can be concluded that all elements necessary for heparin binding and neutralization are present in the C-terminal 129 amino acids of vitronectin. The rCTD now provides a model system for utilizing site-directed mutagenesis in the future to unravel the structural details of the interaction with heparin and other ligands that bind in this region of vitronectin. Other ligands of interest include sulfated lipids, which have been recently shown to interact in the vicinity of the heparin-binding region and to be competitive with glycosaminoglycans for binding (22) .
As with full-length vitronectin, the binding stoichiometry of the rCTD-heparin interaction varied with heparin chain length. Cardin and Weintraub (20) originally modeled the heparin-binding sequence of vitronectin with a heparin octasaccharide. Lane et al. (46) showed that the octasaccharide as well as a pentasaccharide are neutralized by vitronectin. Using heparin with approximately 10 saccharides, essentially one to one binding was achieved with recombinant protein binding to heparin. As the heparin chain was increased, to 20 and 50 saccharides, the stoichiometries increased to 2 and 6 (vitronectin per heparin chain), as would be expected if the vitronectinbinding site interacts with 8 saccharide units on a heparin molecule. These data support the assumption that the vitronectin-binding site on heparin consists of approximately 8 saccharides. Consistent with this view, Lane et al. (46) reported that 6 mol of vitronectin are needed to completely neutralize the anticoagulant activity of the 3rd International Heparin Standard (M r ϳ15,000) against factor Xa. Other studies from this laboratory indicate that the number of binding sites on heparin for full-length plasma-derived vitronectin is somewhat lower due to steric hindrance (23) . By expressing the recombinant CTD, without N-terminal sequences, maximal occupancy of the vitronectin-binding sites (octasaccharides) on the heparin chain is achieved.
Do Secondary Heparin-binding Sequences Contribute Substantially to the Affinity of Vitronectin?-It has been suggested that sequences from the connecting region and the first hemopexin domain in vitronectin might also contribute to heparin binding (21, 50) . It is important to note that heparin affinity for these recombinant peptides was not evaluated quantitatively in the original reports, so there is little supporting evidence for this contention. The study of Yoneda and co-workers (22) used solid-phase heparin binding assays to compare binding of glutathione S-transferase fusion proteins containing the first hemopexin repeat and the second repeat (encompassing the primary heparin-binding site). There is at least an order of magnitude difference in binding between the two sequences from vitronectin, with weaker apparent binding to the first hemopexin domain, but no comparison was made with purified plasma vitronectin. With this in mind, it was important to evaluate whether the primary heparin-binding site could account for the full extent of heparin binding activity.
As mentioned above, mathematical fits to the binding isotherms generated by the interaction of vitronectin with labeled heparin have always been satisfactory with only a single class of binding sites (23) . Competition studies with other sulfated glycosaminoglycans in this work give a similar result. The binding of dextran sulfate or fucoidan to vitronectin completely displaces the labeled heparin from the protein, and mathematical modeling of the system indicates only a single class of binding sites. A separate line of evidence refuting the importance of a secondary binding site on vitronectin is the observation that chemically modified vitronectin generated using an arginine-reactive probe exhibits a significant reduction in heparin binding upon the labeling of only 1-2 residues. In this study, the label has been localized to arginine residues within the cyanogen bromide fragment-(341-380). This is the same polypeptide that was characterized in the original identification of the primary site containing consensus heparin-binding motifs (4) . Furthermore, the fact that a recombinant domain from the C terminus of vitronectin and full-length plasmaderived vitronectin do not differ in their affinities for heparin supports the idea that all of the structural elements needed for heparin binding are present in the recombinant C-terminal domain and obviates the need to consider secondary binding sites as significant.
Do Secondary Heparin-binding Sequences Become Functional in the Altered Conformation of Vitronectin Adopted in the
Multimer?-With emerging biophysical and structural data, researchers have come to appreciate the conformational flexibility of vitronectin, which exists primarily in a monomeric form in plasma but converts to a multimer that may resemble the extracellular matrix conformation upon denaturation and subsequent refolding (26, 29, 51) . The prevailing theory has been that vitronectin function is regulated by this conformational lability, with the molecule expressing different functional repertoires depending on its oligomeric state. A prominent interpretation of this model has been that the functional domains described above vary in their degree of exposure, depending on the conformational state of the molecule.
The recent work of Yoneda and colleagues (22) on recombinant fusion proteins representing hypothetical domains within vitronectin has deviated somewhat from traditional lines of thought about the conformational alterations in vitronectin. Their studies demonstrate glycosaminoglycan binding to the first hemopexin domain, albeit significantly weaker than observed with the second hemopexin domain that contains the primary heparin-binding consensus site. This result is interpreted by these workers as a means of providing a second heparin-binding site that can become functional in the conformationally altered form of vitronectin. In this scenario, the secondary binding sequences are now the cryptic ones in the native form of vitronectin. Note again that these measurements were performed using solid-phase technology and that true ligand affinities cannot be derived from these data. Furthermore, as the authors acknowledge, there is no direct evidence for altered exposure of the secondary sites. Clearly, more rigorous experimentation is needed to make this determination.
Even so, work from this laboratory has clearly disputed a buried orientation of the primary heparin site, and the evaluations of heparin-binding stoichiometry for the native and multimeric forms of vitronectin have bearing on this discussion. Rather than inducing changes in affinity (or "exposure") of the primary binding site on vitronectin, denaturation and renaturation of vitronectin lead to a multimeric form of vitronectin that binds to heparin with a different stoichiometry than the native protein. The monomeric native protein exhibits 1:1 binding, but the multimer exhibits a 2:1 stoichiometry, in which two vitronectin protomers within the multimer contact a single heparin molecule. This multivalent binding gives apparently tighter binding to heparin when measured by non-solution methods (24) . A critical point is that the 2:1 stoichiometry represents two separate vitronectin protomers contacting a single heparin molecule, rather than two different binding sites within the same protomer contacting heparin. If the latter were the case, then an actual reduction in stoichiometry would be measured, i.e. the available vitronectin-binding sites on heparin would be saturated with a lower concentration of vitronectin protomers. That is, if there were a secondary heparinbinding site that became functional in the altered conformation of vitronectin, a stoichiometry of 0.5:1 (vitronectin:heparin) would be expected instead of the 2:1 stoichiometry observed. These quantitative analyses argue against the contribution of secondary sites to binding after unfolding of vitronectin. For further consideration of the ways in which protein:ligand binding stoichiometries can be influenced by multiple binding sites on either heparin or the protein, the reader is referred to published work on antithrombin or thrombin binding to heparin (45, 52, 53) .
Does Liberation of the Heparin-binding Region from N-terminal Sequences Alter Exposure of the Primary Binding Site?-
The data presented here are consistent with exposure of the heparin-binding site on folded vitronectin. If interactions with N-terminal sequences mask the heparin-binding site of vitronectin, expression of the isolated C-terminal domain separate from upstream sequences should in effect "unmask" the heparin-binding site. Thus the binding affinity for recombinant CTD should be higher than observed for intact plasma vitronectin. This is not the case. In two assays, the recombinant protein showed similar affinity for heparin to monomeric plasma-derived vitronectin, contradicting the argument that interactions with other residues mask the heparin-binding site.
This observation is consistent with other work from this laboratory (23) that has revealed that both native and multimeric vitronectin bind heparin with the same affinity. The alignment of multiple binding sites in multimeric vitronectin increases their local concentration. In solid-phase assays, the end result is that multimeric vitronectin appears to bind heparin more tightly than the native folded molecule. Solution biochemistry indicates that differences in the binding of heparin to altered forms of vitronectin result from changes in binding stoichiometry due to the alignment of multiple heparinbinding sites on multimeric vitronectin, and not from encryption of the binding site in native vitronectin. Also, observations that this region of the molecule is highly susceptible to proteolysis by thrombin (18) , plasmin (8, 18) , and an endogenous protease that cleaves one allelic variant of vitronectin between 379 and 380 (54) indicate that residues from the heparin-binding region must be presented on the surface of native vitronectin. Moreover, the susceptibility of native vitronectin to phosphorylation at serine 378 (55, 56) and chemical modification of an arginine within the heparin-binding sequence (33) corroborate the surface orientation of the heparin-binding site. Altogether, the data support the concept that the C-terminal region of vitronectin is fully exposed in native vitronectin and functions autonomously with respect to heparin binding.
